Trial · NCT03203642
Results by group18
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 18 of 18
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline in Height Adjusted Total Kidney Volume (htTKV) at Month 12 | Tesevatinib | 0.0236 | Standard Error 0.0059 | milliliters per meter | |
| Change From Baseline in Height Adjusted Total Kidney Volume (htTKV) at Month 12 | Placebo | 0.0288 | Standard Error 0.0057 | milliliters per meter | |
| Change From Baseline in Height Adjusted Total Kidney Volume at Month 18 | Tesevatinib | 0.0383 | Standard Error 0.0081 | milliliters per meter | |
| Change From Baseline in Height Adjusted Total Kidney Volume at Month 18 | Placebo | 0.0425 | Standard Error 0.0075 | milliliters per meter | |
| Change From Baseline in Height Adjusted Total Kidney Volume at Month 24 | Tesevatinib | 0.0485 | Standard Error 0.0103 | milliliters per meter | |
| Change From Baseline in Height Adjusted Total Kidney Volume at Month 24 | Placebo | 0.0607 | Standard Error 0.0095 | milliliters per meter | |
| Change From Baseline in Height Adjusted Total Kidney Volume at End of Study | Tesevatinib | 0.0604 | Standard Error 0.0090 | milliliters per meter | |
| Change From Baseline in Height Adjusted Total Kidney Volume at End of Study | Placebo | 0.0589 | Standard Error 0.0094 | milliliters per meter | |
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Tesevatinib | 37 | Participants | ||
| Number of Participants With Treatment-emergent Adverse Events (TEAEs) | Placebo | 40 | Participants | ||
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Months 12, 18, 24 and End of Study | Tesevatinib | Month 12 | -6.8032 | Standard Error 1.2293 | mL/min/1.73m^2 |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Months 12, 18, 24 and End of Study | Placebo | Month 12 | -2.1780 | Standard Error 1.1709 | mL/min/1.73m^2 |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Months 12, 18, 24 and End of Study | Tesevatinib | Month 18 | -7.3626 | Standard Error 1.6645 | mL/min/1.73m^2 |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Months 12, 18, 24 and End of Study | Placebo | Month 18 | -3.8950 | Standard Error 1.6971 | mL/min/1.73m^2 |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Months 12, 18, 24 and End of Study | Tesevatinib | Month 24 | -9.7307 | Standard Error 1.4708 | mL/min/1.73m^2 |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Months 12, 18, 24 and End of Study | Placebo | Month 24 | -6.4070 | Standard Error 1.4138 | mL/min/1.73m^2 |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Months 12, 18, 24 and End of Study | Tesevatinib | End of study | -3.2757 | Standard Error 0.5990 | mL/min/1.73m^2 |
| Change From Baseline in Estimated Glomerular Filtration Rate (eGFR) at Months 12, 18, 24 and End of Study | Placebo | End of study | -3.7497 | Standard Error 0.6323 | mL/min/1.73m^2 |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT03203642/results